Singapore President visits Sapigen Biologix, a Bharat Biotech subsidiary built at investment of Rs 1500 Crore in Orissa

The state-of-the-art vaccine manufacturing plant is built to produce 10 different vaccines, and create more than 2000 direct jobs and 1500 indirect employment opportunities

0
78
New Delhi: The President of Singapore, Tharman Shanmugaratnam, visited Sapigen Biologix at its state-of-the-art vaccine manufacturing plant located in the Odisha Biotech Park in Andharua, Bhubaneswar. He was accompanied by a high-level delegation that included his top ministerial colleagues and business leaders.
Sapigen Biologix, a subsidiary of Bharat Biotech is touted to be among the world’s largest anchor facility.
The President was welcomed by Dr. Krishna Ella, Founder of Sapigen and Bharat Biotech; Dr. Suchitra Ella, Founder and Managing Director of Bharat Biotech; Dr. Raches Ella, Managing Director of Sapigen Biologix; Dr. Jalachari Ella, Director of Sapigen Biologix; and senior executives of the firm.
The Singapore President took a tour of the manufacturing facilities, following which he held high level interaction with the leadership of Sapigen Biologix led by Dr. Krishna Ella and Mrs. Suchitra Ella. The plaque in honour of the President’s visit to the facility was also unveiled during his visit.
“We are deeply honoured to welcome the President of Singapore, His Excellency Tharman Shanmugaratnam, to our facility today and are proud to demonstrate the innovative work being done at this expansive multi-vaccine production facility to further accelerate vaccine development and contribute to the health and well-being of people around the world,” said Dr. Krishna Ella, Founder of Sapigen Biologix.
Dr. Ella added, “We thank the Government of Odisha, the Government of India, regulators, and our team for making this world-class, global-scale vaccine production facility a reality. The Sapigen Biologix facility marks our commitment to global public health, affordable vaccines, and strengthening India’s self-reliance and pandemic preparedness. There are no vaccine or biotech manufacturing plants between Hyderabad and Arunachal Pradesh. We are extremely proud to be bringing the knowledge-based industry and the first vaccine/biotech manufacturing plant to the eastern part of India. We hope to spur activities in knowledge-based industries in the eastern part of India instead of concentrating them in the southern and western parts of the country.”
Dr. Raches Ella, Managing Director of Sapigen Biologix, said, “On behalf of everyone at Sapigen Biologix, I extend our heartfelt gratitude to the Hon’ble President of Singapore for visiting our facility today. The significance of this project reaches far beyond Odisha. This facility will position Odisha and India on the global map as the largest vaccine production and supply hub—not only for global distribution but also in alignment with our broader vision of fostering regional economic growth, nurturing local talent, and providing sustainable preventive healthcare solutions to communities worldwide.”
Sapigen Biologix will focus on the production of key vaccines aimed at addressing global health challenges,” added Dr. Raches Ella, “The first and most significant vaccine to be produced at Sapigen Biologix’s cGMP production facility will be the world’s second oral cholera vaccine, Hillchol (BBV131). This novel single-strain vaccine marks an important step forward in our efforts to combat cholera worldwide. The timing of this rollout is crucial, given the global shortage of oral cholera vaccines (OCVs), as evidenced by recent deaths in Angola due to pandemic cholera.
Dr. Ella added, “We thank the Government of Odisha, the Government of India, regulators, and our team for making this world-class, global-scale vaccine production facility a reality. The Sapigen Biologix facility marks our commitment to global public health, affordable vaccines, and strengthening India’s self-reliance and pandemic preparedness. There are no vaccine or biotech manufacturing plants between Hyderabad and Arunachal Pradesh. We are extremely proud to be bringing the knowledge-based industry and the first vaccine/biotech manufacturing plant to the eastern part of India. We hope to spur activities in knowledge-based industries in the eastern part of India instead of concentrating them in the southern and western parts of the country.”
Dr. Raches Ella, Managing Director of Sapigen Biologix, said, “On behalf of everyone at Sapigen Biologix, I extend our heartfelt gratitude to the Hon’ble President of Singapore for visiting our facility today. The significance of this project reaches far beyond Odisha. This facility will position Odisha and India on the global map as the largest vaccine production and supply hub—not only for global distribution but also in alignment with our broader vision of fostering regional economic growth, nurturing local talent, and providing sustainable preventive healthcare solutions to communities worldwide.”
Sapigen Biologix will focus on the production of key vaccines aimed at addressing global health challenges,” added Dr. Raches Ella, “The first and most significant vaccine to be produced at Sapigen Biologix’s cGMP production facility will be the world’s second oral cholera vaccine, Hillchol (BBV131). This novel single-strain vaccine marks an important step forward in our efforts to combat cholera worldwide. The timing of this rollout is crucial, given the global shortage of oral cholera vaccines (OCVs), as evidenced by recent deaths in Angola due to pandemic cholera.
The vaccines produced in Sapigen Biologix will be supplied to several parts of the world and will strengthen the name of Odisha and India in the vaccines and biotechnology prowess.